Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415887 | 0.97 | ACHE (0.50) | ACHEKMT2ABCHEMEN1 | |
| SCHEMBL6420801 | 0.82 | TLR8 (0.51) | ACHE | |
| SCHEMBL12654842 | 0.80 | HRH3 (0.62) | ACHEBCHE | |
| SCHEMBL6420492 | 0.79 | TLR8 (0.51) | ACHE | |
| SCHEMBL12655047 | 0.79 | HRH3 (0.48) | ACHEKMT2ABCHEMEN1 | |
| SCHEMBL6420511 | 0.78 | TLR8 (0.50) | ACHEBCHE | |
| SCHEMBL12655044 | 0.76 | HRH3 (0.51) | ACHEKMT2ABCHEMEN1 | |
| SCHEMBL12654881 | 0.75 | HRH3 (0.53) | ACHEKMT2ABCHEMEN1 | |
| SCHEMBL5733452 | 0.75 | ACHE (0.47) | ACHEKMT2ABCHEMEN1 | |
| SCHEMBL5733334 | 0.75 | ACHE (0.44) | ACHEKMT2ABCHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951866-B2 | Bicyclic pyrimidine compounds and therapeutic use thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-10-04 | — | — | US | disclosed |
| EP-1110951-B1 | PYRIMIDINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-20030105323-A1 | Pyrimidine derivative | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-06-05 | — | — | US | disclosed |
| US-6458798-B1 | HAS AN INHIBITORY ACTIVITY OF PRODUCTION OF TH2 TYPE CYTOKINES SUCH AS IL-4, IL-5, ETC., AND IS USEFUL AS AN THERAPEUTIC AGENT FOR ALLERGIC DISEASES, AUTOIMMUNE DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATHOSUS, ETC., AND ACQUIRED | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1110951-A1 | PYRIMIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105323-A1 | Pyrimidine derivative | IL5, IL4, IL15 | ACHE 4681/4885KMT2A 2905/4885BCHE 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.